At the Oppenheimer Healthcare Conference, Aclaris management emphasized two key upcoming data catalysts: a midyear Phase II primary endpoint readout for its atopic dermatitis program and an interim analysis for its asthma trial slated for the third quarter of 2026.

Executives outlined that positive AD Phase II results could support a regulatory submission by mid-2026 and that asthma data could trigger advancement into pivotal studies, underlining the potential to expand the company’s immunology portfolio.

Earlier the same day, Aclaris previewed its fourth-quarter performance, citing trends in product revenue and a reduction in net loss versus the prior year, and reiterated plans to cut operating expenses and extend cash runway through targeted cost-saving initiatives.